Brief: Karyopharm Therapeutics Q2 Net Income USD -32.63 Million
02/08/2023 12:30
Aug 02 (Reuters) - Karyopharm Therapeutics Q2 operating expenses USD 67.152 million. * Q2 product revenue USD 28.46 million * Q2 operating income USD -29.573 million * Outlook FY Revenue USD 145-160 Million
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview